Abstract
Post-TB lung disease (PTLD) causes a significant burden of global disease. Fibrosis is a central component of many clinical features of PTLD. To date, we have a limited understanding of the mechanisms of TB-associated fibrosis and how these mechanisms are similar to or dissimilar from other fibrotic lung pathologies. We have adapted a mouse model of TB infection to facilitate the mechanistic study of TB-associated lung fibrosis. We find that the morphologies of fibrosis that develop in the mouse model are similar to the morphologies of fibrosis observed in human tissue samples. Using Second Harmonic Generation (SHG) microscopy, we are able to quantify a major component of fibrosis, fibrillar collagen, over time and with treatment. Inflammatory macrophage subpopulations persist during treatment; matrix remodeling enzymes and inflammatory gene signatures remain elevated. Our mouse model suggests that there is a therapeutic window during which adjunctive therapies could change matrix remodeling or inflammatory drivers of tissue pathology to improve functional outcomes after treatment for TB infection.
Introduction
Tuberculosis (TB) is often framed as a battle won once the bacteria are eradicated. However, for up to 50% of survivors, a clinical "cure" is followed by Post-TB Lung Disease (PTLD)—a suite of permanent respiratory issues including cavitation and extensive fibrosis. This scarring leads to lifelong disability and increased mortality, yet the underlying mechanisms remain poorly understood.
A primary bottleneck in PTLD research has been the lack of a reliable small animal model. Standard mouse models of TB often fail to develop the complex, necrotic, and fibrotic lesions characteristic of human disease. Without a model that replicates human-like pathology, researchers have been unable to test host-directed therapies (HDTs) designed to halt the scarring process while antibiotics manage the infection.
Developing a Representative Model of TB Fibrosis
To bridge the gap between clinical observation and laboratory modeling, researchers first characterized the "histopathologic spectrum" of fibrosis in a large repository of human lung tissues from Durban, South Africa. They identified specific patterns, including interstitial, subpleural, and alveolar replacement fibrosis, across the clinical continuum of latent, active, and healed TB.
The team then adapted the C3HeB/FeJ mouse strain, which is known for developing human-like necrotic lesions. By comparing the mouse pathology to the human benchmarking data, they confirmed that this model successfully replicates the diverse fibrotic patterns found in patients, including the development of fibrous caps around necrotic lesions.
Quantifying Tissue Remodeling with SHG Microscopy
To move beyond subjective histological staining, the study employed Second Harmonic Generation (SHG) microscopy. SHG is a label-free, nonlinear optical imaging technique that specifically targets non-centrosymmetric structures like fibrillar collagen. This allowed the team to quantitatively map the "stuff" of scars in the lungs over time.
The results showed a significant increase in fibrillar collagen density by 12 weeks post-infection. Crucially, this collagen accumulation did not resolve even after the administration of standard "RIPE" antibiotic treatment (Rifampin, Isoniazid, Pyrazinamide, and Ethambutol), indicating that the structural damage of TB is highly persistent.
The Decoupling of Infection and Inflammation
A major insight from the study was the decoupling of bacterial load and tissue inflammation. While antibiotic treatment successfully cleared the bacteria, inflammatory infiltrates continued to expand or persist. Multi-omic analysis, including bulk RNA sequencing (RNAseq), revealed that inflammatory gene signatures remained stubbornly high eight weeks into treatment.
Key findings regarding the persistence of tissue damage include:
- Matrix Metalloproteinases (MMPs): Enzymes responsible for breaking down the lung's structural matrix, specifically Mmp8, Mmp12, and Mmp14, remained elevated during treatment. This suggests that the remodeling process—and thus the scarring—continues even as the pathogen is cleared.
- Pro-fibrotic Macrophages: Using flow cytometry, the team identified specific macrophage subpopulations (Interstitial and $Ly6c^{hi}$ macrophages) that persist during treatment. These cells expressed transcriptional signatures previously linked to other fibrotic conditions, such as Idiopathic Pulmonary Fibrosis (IPF).
Defining a Therapeutic Window
Transcriptional profiling showed that pathways for IL-10 signaling and Type I/II Interferons remained upregulated weeks into the antibiotic regimen. This evidence suggests an active biological "therapeutic window" where adjunctive therapies—such as targeted MMP inhibitors or anti-fibrotic agents like pirfenidone—could be administered alongside antibiotics.
By targeting these persistent inflammatory drivers and matrix-remodeling enzymes, it may be possible to intervene in the scarring process and improve the long-term functional outcomes for TB survivors, finally addressing the permanent sequelae of the disease.
Summary updated